ClinicalTrials.gg
CompletedNCT05056246Updated Feb 25, 2025Results posted

Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

A Phase 1 interventional study of AMG 133 in Healthy Participants, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the pharmacokinetics (PK) of AMG 133 after single subcutaneous (SC) administration in healthy Japanese and Caucasian participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • Maridebart Cafraglutide
  • Japanese participants
  • Caucasian participants
  • AMG 133
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Healthy male or female participants between 18 and 65 years of age (inclusive) at the time of Screening (Japanese participants must be first-generation Japanese)
  2. In good health, determined by no findings from medical history, physical examination, , vital signs measurements, and clinical laboratory evaluations
  3. between 18 and 30 kg/m\^2 at the time of Screening
  4. Females of nonchildbearing potential

Key Exclusion Criteria:

  1. History or evidence, at Screening or Check-in, of clinically significant disorder, condition, or disease
  2. History or current signs or symptoms of cardiovascular disease
  3. History or evidence of clinically significant arrhythmia at Screening, including any clinically significant findings on the ECG taken at Check-in
  4. History of , intolerance, or allergy to any drug compound, food, or other substance
  5. Positive or panel and/or positive test at Screening
  6. History of alcoholism or drug/chemical abuse within 1 year prior to Check-in
  7. Use of tobacco- or nicotine-containing products within 6 months prior to Check-in
  8. Positive test for illicit drugs, cotinine (tobacco or nicotine use), and/or alcohol use at Screening or Check-in
  9. Female participants with a positive pregnancy test at Screening or Check-in
  10. Female participants lactating/breastfeeding or who plans to breastfeed during the study through 90 days after the end of study (EOS) visit
  11. Donation of blood from 3 months prior to Check-in, plasma from 2 weeks prior to Check-in, or from 6 weeks prior to Check-in
  12. Unwilling to abide with study restrictions
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Japanese Participants: AMG 133 Low Dose

    Healthy Japanese participants will receive the low dose of AMG 133 as a SC injection on Day 1 of the study.

    Drug: AMG 133

  • Experimental
    Japanese Participants: AMG 133 Medium Dose

    Healthy Japanese participants will receive the medium dose of AMG 133 as a SC injection on Day 1 of the study.

    Drug: AMG 133

  • Experimental
    Japanese Participants: AMG 133 High Dose

    Healthy Japanese participants will receive the high dose of AMG 133 as a SC injection on Day 1 of the study.

    Drug: AMG 133

  • Experimental
    Caucasian Participants: AMG 133 Medium Dose

    Healthy Caucasian participants will receive the medium dose of AMG 133 as a SC injection on Day 1 of the study.

    Drug: AMG 133

  • Experimental
    Caucasian Participants: AMG 133 High Dose

    Healthy Caucasian participants will receive the high dose of AMG 133 as a SC injection on Day 1 of the study.

    Drug: AMG 133

Interventions

  • Solution for SC injection

    Also known as: maridebart cafraglutide

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Intact AMG 133

    Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

    Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose

  2. Cmax of Total AMG 133

    Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

    Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose

  3. Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of Intact AMG 133

    Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

    Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose

  4. AUClast of Total AMG 133

    Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

    Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose

  5. Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Intact AMG 133

    Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

    Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose

  6. AUCinf of Total AMG 133

    Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

    Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose

Secondary outcomes

  1. Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

    A TEAE was defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with AMG 133 that started during or after dosing, or started prior to dosing and increased in severity after dosing. Clinically significant changes from baseline in clinical laboratory tests, 12-lead electrocardiograms (ECGs) and vital signs were also reported as TEAEs.

    Time frame: Day 1 to Day 120

  2. Number of Participants With a Positive Anti-AMG 133 Binding Antibody Result

    Blood samples were collected at specific times during the study for the measurement of anti-AMG 133 binding antibodies from participants who received AMG 133.

    Time frame: Days 1, 15, 29, 57 and 120

07

Results

Posted Feb 25, 2025

Participant flow

Healthy Japanese and Caucasian participants were enrolled at a single center in the United States between 10 September 2021 and 08 April 2022.

Participant flow — Overall Study
MilestoneJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
Started67777
Received amg 13367777
Completed66756
Not completed01021
Withdrew: Adverse event00001
Withdrew: Lost to follow-up00020
Withdrew: Withdrawal by subject01000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Intact AMG 133

Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

Time frame:
Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
Reported as:
Geometric mean · μg/mL
Maximum Observed Plasma Concentration (Cmax) of Intact AMG 133
μg/mLJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
Maximum Observed Plasma Concentration (Cmax) of Intact AMG 13312.3 ± 57.322.7 ± 24.144.9 ± 34.622.5 ± 33.955.0 ± 26.7
PrimaryCmax of Total AMG 133

Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

Time frame:
Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
Reported as:
Geometric mean · μg/mL
Cmax of Total AMG 133
μg/mLJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
Cmax of Total AMG 13313.2 ± 56.324.8 ± 25.648.4 ± 32.020.8 ± 24.558.7 ± 24.8
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of Intact AMG 133

Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

Time frame:
Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
Reported as:
Geometric mean · h*ug/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of Intact AMG 133
h*ug/mLJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of Intact AMG 13310600 ± 45.219400 ± 36.033500 ± 20.517200 ± 42.435700 ± 31.1
PrimaryAUClast of Total AMG 133

Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

Time frame:
Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
Reported as:
Geometric mean · h*ug/mL
AUClast of Total AMG 133
h*ug/mLJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
AUClast of Total AMG 13314800 ± 41.828300 ± 37.247700 ± 21.120800 ± 41.449600 ± 30.9
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Intact AMG 133

Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

Time frame:
Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
Reported as:
Geometric mean · h*ug/mL
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Intact AMG 133
h*ug/mLJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Intact AMG 13310700 ± 44.919600 ± 36.433900 ± 20.417300 ± 43.336000 ± 31.6
PrimaryAUCinf of Total AMG 133

Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.

Time frame:
Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
Reported as:
Geometric mean · h*ug/mL
AUCinf of Total AMG 133
h*ug/mLJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
AUCinf of Total AMG 13315600 ± 40.530100 ± 39.250100 ± 21.821800 ± 45.451500 ± 32.5
SecondaryNumber of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

A TEAE was defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with AMG 133 that started during or after dosing, or started prior to dosing and increased in severity after dosing. Clinically significant changes from baseline in clinical laboratory tests, 12-lead electrocardiograms (ECGs) and vital signs were also reported as TEAEs.

Time frame:
Day 1 to Day 120
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
ParticipantsJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)66777
SecondaryNumber of Participants With a Positive Anti-AMG 133 Binding Antibody Result

Blood samples were collected at specific times during the study for the measurement of anti-AMG 133 binding antibodies from participants who received AMG 133.

Time frame:
Days 1, 15, 29, 57 and 120
Reported as:
Count of participants · Participants
Number of Participants With a Positive Anti-AMG 133 Binding Antibody Result
ParticipantsJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
Number of Participants With a Positive Anti-AMG 133 Binding Antibody Result33310

Adverse events

Collected over All-cause mortality was collected from enrolment to end of study (median [min,max]: 4.42 months [1.51, 5.42 months]. Serious adverse events and other adverse events were collected from Day 1 to Day 120.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Japanese Participants: AMG 133 Low Dose0/6 (0%)0/6 (0%)6/6 (100%)
Japanese Participants: AMG 133 Medium Dose0/7 (0%)0/7 (0%)6/7 (85.7%)
Japanese Participants: AMG 133 High Dose0/7 (0%)1/7 (14.3%)7/7 (100%)
Caucasian Participants: AMG 133 Medium Dose0/7 (0%)0/7 (0%)7/7 (100%)
Caucasian Participants: AMG 133 High Dose0/7 (0%)0/7 (0%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
Road traffic accidentInjury, poisoning and procedural complications0/60/71/70/70/7
Cervical spinal stenosisMusculoskeletal and connective tissue disorders0/60/71/70/70/7
Most frequent other events
Showing 10 of 38
Most frequent other events
EventJapanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High Dose
NauseaGastrointestinal disorders5/66/77/77/77/7
VomitingGastrointestinal disorders4/66/77/77/77/7
HeadacheNervous system disorders2/63/75/73/73/7
ParaesthesiaNervous system disorders0/60/71/70/73/7
Decreased appetiteMetabolism and nutrition disorders2/61/71/71/72/7
FatigueGeneral disorders0/60/72/70/70/7
COVID-19Infections and infestations0/60/70/72/72/7
MyalgiaMusculoskeletal and connective tissue disorders1/60/71/70/72/7
Abdominal painGastrointestinal disorders1/60/70/70/70/7
Gastrooesophageal reflux diseaseGastrointestinal disorders1/60/70/70/71/7

Baseline characteristics

Safety Population: Included all participants who received at least 1 dose of AMG 133.

Age, Continuous
Age, Continuous(years)Japanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High DoseTotal
Mean57.3 ± 4.8055.0 ± 5.3552.9 ± 13.9043.0 ± 14.5949.0 ± 11.9351.3 ± 11.58
Sex: Female, Male
Sex: Female, Male(Participants)Japanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High DoseTotal
Female3341213
Male3436521
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Japanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High DoseTotal
Hispanic or Latino000246
Not Hispanic or Latino6775328
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Japanese Participants: AMG 133 Low DoseJapanese Participants: AMG 133 Medium DoseJapanese Participants: AMG 133 High DoseCaucasian Participants: AMG 133 Medium DoseCaucasian Participants: AMG 133 High DoseTotal
White0007714
Japanese6770020
08

Study locations

1 site
  • WCCT Global LLC
    Cypress, California 90630-4738, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Apr 2022, 6 months.

Results were first posted in Feb 2025, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2021
First posted
Sep 24, 2021
StartActual
Sep 10, 2021
Primary completionActual
Apr 8, 2022
CompletionActual
Apr 8, 2022
Results first posted
Feb 25, 2025
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05056246
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 24, 2021
Start date
Sep 10, 2021
Primary completion
Apr 8, 2022
Completion
Apr 8, 2022
Results posted
Feb 25, 2025
Last update
Feb 25, 2025

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion